Document Detail


Use of injectable spasticity management agents in a cancer center.
MedLine Citation:
PMID:  23142955     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: This study aims to analyze the utilization and effectiveness of injectable spasticity medications by the physiatry team at a referral-based tertiary cancer center.
METHODS: A retrospective review and analysis of patient and injection characteristics were obtained from patients who had received onabotulinum toxin or phenol nerve block injections from December 1, 2007 through January 31, 2012. Out of 3,724 physiatry consultations during this period, 20 (less than 1 %) different cancer patients received a total of 54 total procedures.
RESULTS: The majority of patients (17/20, 85 %) had a positive response to the injection. A positive response to the injection was defined by: (1) if the patient qualified to receive and was given another injection or (2) if there is a record of improvement if they did not receive another injection. A total of ten of 20 (50 %) patients received only one injection. Of these, seven of ten (70 %) reported a positive response to the injected agent. Those with only one injection tended to live farther away and die sooner. Four of 54 (7 %) injection procedures resulted in undesirable reported side effects (two for phenol, two for botulinum toxin). Nine of 54 (17 %) procedures occurred while the patients were on a chemotherapy protocol. All patients were injected at least 1 year out from initial diagnosis.
Authors:
Jack Fu; Carolina Gutiérrez; Eduardo Bruera; Ying Guo; Shana Palla
Related Documents :
24812495 - Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with t...
24647515 - The characteristics of referring facilities and transferred hand surgery patients: fact...
23561005 - Telephone consultations in place of face to face out-patient consultations for patients...
24790025 - Short-term outcomes of sport- and recreation-related concussion in patients admitted to...
19839975 - Allergic asthma in patients with common variable immunodeficiency.
2403505 - Outcome after assisted ventilation in children with acquired immunodeficiency syndrome.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural     Date:  2012-11-11
Journal Detail:
Title:  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer     Volume:  21     ISSN:  1433-7339     ISO Abbreviation:  Support Care Cancer     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-01     Completed Date:  2013-09-23     Revised Date:  2014-05-08    
Medline Journal Info:
Nlm Unique ID:  9302957     Medline TA:  Support Care Cancer     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1227-32     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Botulinum Toxins, Type A / administration & dosage,  therapeutic use*
Cancer Care Facilities
Female
Humans
Injections
Male
Middle Aged
Muscle Spasticity / drug therapy*,  etiology
Neoplasms / complications
Nerve Block / methods*
Neuromuscular Agents / administration & dosage,  therapeutic use
Phenol / administration & dosage,  therapeutic use*
Retrospective Studies
Treatment Outcome
Grant Support
ID/Acronym/Agency:
P30 CA016672/CA/NCI NIH HHS; R01 CA122292/CA/NCI NIH HHS; R01 CA124481/CA/NCI NIH HHS; R01 NR010162/NR/NINR NIH HHS; R01CA016672/CA/NCI NIH HHS; R01CA122292-01/CA/NCI NIH HHS; R01CA124481-01/CA/NCI NIH HHS; R01NR010162-01A1/NR/NINR NIH HHS
Chemical
Reg. No./Substance:
0/Neuromuscular Agents; 0/onabotulinumtoxinA; 339NCG44TV/Phenol; EC 3.4.24.69/Botulinum Toxins, Type A
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Copeptin constitutes a novel biomarker of degenerative aortic stenosis.
Next Document:  A new approach for rhenium(VII) recovery by using modified brown algae Laminaria japonica adsorbent.